EMA: First Adapted COVID-19 Vaccines Expected In September
Data Still Awaited On Valneva Vaccine & Molnupiravir
Executive Summary
As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.
You may also be interested in...
Coronavirus Notebook: New EU Body To Advise On Future Pandemic Actions, Valneva Awaits EMA Verdict On Vaccine Candidate
French health tech firm NOVA has produced a model for assessing the impact of non-pharmaceutical COVID-19 interventions on clinical trials of respiratory tract drugs, and Moderna’s Spikevax has been OKd for younger children in Great Britain.
Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial
RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found no links between the mRNA vaccines and autoimmune hepatitis.
Coronavirus Notebook: EMA Starts Review Of HIPRA’s COVID-19 Vaccine, Moderna To Set Up Australian mRNA Plant
There is no shortage of news relating to potential new COVID-19 treatments and vaccines. Among other things, zapnometinib, an antiviral compound being developed by German firm Atriva, has shown strong efficacy against Omicron in a Phase I study. Also, Sweden’s ISR and Iconovo have expanded their collaboration deal to accelerate the development of an inhaled COVID-19 vaccine.